Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions
Version of Record online: 11 APR 2007
RCOG 2007 BJOG An International Journal of Obstetrics and Gynaecology
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 114, Issue 5, pages 555–562, May 2007
How to Cite
Aldrich, T. and Winikoff, B. (2007), Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions. BJOG: An International Journal of Obstetrics & Gynaecology, 114: 555–562. doi: 10.1111/j.1471-0528.2007.01274.x
- Issue online: 11 APR 2007
- Version of Record online: 11 APR 2007
- Accepted 23 November 2006.
- 2Alan Guttmacher Institute. Women, Families and the Future. New York, NY: AGI, 1994.
- 3Maternal Health and Safe Motherhood Programme. Abortion: A Tabulation of Available Data on the Frequency and Mortality of Unsafe Abortion, 2nd edn. Geneva, Switzerland: WHO, 1994..
- 11Consensus Statement: Instructions for Use-Abortion Induction with Misoprostol in Pregnancies up to 9 Weeks LMP. Expert Meeting on Misoprostol sponsored by Reproductive Health Technologies Project and Gynuity Health Projects. New York: Gynuity Health Projects, 2003.
- 19Instituting medical abortion services: changes in outcome and acceptability related to provider experience. J Am Med Womens Assoc 2000;55(3 Suppl):173–6., , , , .
- 1c Royal College of Obstetricians and Gynaecologists. Induced Abortion. RCOG Guideline 11, London: Royal College of Obstetricians and Gynaecologists; 1997.